Devices & Diagnostics

Medtech cos enter fray to compete for investor attention at Tenn. conference for start-ups

If you are a start-up located everywhere else (read outside Silicon Valley and NYC) then Memphis, Tennessee is the place to be Feb. 10 to 12. That’s because Everywhere Else.Co is hosting its startup conference where attendees can learn how to crowdfunding and raise capital, get a crash course on accounting and legal as well […]

If you are a start-up located everywhere else (read outside Silicon Valley and NYC) then Memphis, Tennessee is the place to be Feb. 10 to 12.

That’s because Everywhere Else.Co is hosting its startup conference where attendees can learn how to crowdfunding and raise capital, get a crash course on accounting and legal as well as learn what other entrepreneurs experienced as part of an accelerator program. And all for the ticket price of $60.

But there’s a fun element too. Participating start-ups are being invited to submit a three-minute video. People have already begun voting and the top five vote-getters will get a chance to pitch to the judging and investor panel on Feb. 11.

Here’s a medical device firm that has entered the fray and here’s their video. The company is HandMinder, which makes a stroke rehabilitation glove intended to improve hand function.

A second medical technology company has also submitted a video. Bionanonvations Corp. brings bionanotechnology to the realm of medical devices and has developed a way to detect bacterial infection quickly. It’s TestQuick technology reduces the time to detect an infection to 30 minutes from four to five days, according to the company. It is a hand-held device that can take blood or mucous to determine whether there is bacterial infection.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.